Profound Medical (PROF)
(Delayed Data from NSDQ)
$7.69 USD
+0.21 (2.81%)
Updated Oct 11, 2024 03:59 PM ET
After-Market: $7.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.69 USD
+0.21 (2.81%)
Updated Oct 11, 2024 03:59 PM ET
After-Market: $7.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum F VGM
Zacks News
Profound Medical (PROF) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of 11.11% and 9.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Durect (DRRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Durect (DRRX) delivered earnings and revenue surprises of 0% and 21.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 28.89% and 25.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for April 27th
by Zacks Equity Research
FRPT, PING, and PROF have been added to the Zacks Rank #5 (Strong Sell) List on April 27, 2022
Profound Medical (PROF) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics (UTHR) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of -37.67% and 1.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of -11.54% and -36.58%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Profound Medical (PROF) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PROFOUND MEDICL (PROF) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
PROFOUND MEDICL (PROF) delivered earnings and revenue surprises of -34.62% and 15.98%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
PROFOUND MEDICL (PROF) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
PROFOUND MEDICL (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate PROFOUND MEDICL (PROF) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
PROFOUND MEDICL (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PROFOUND MEDICL (PROF) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
PROFOUND MEDICL (PROF) delivered earnings and revenue surprises of -40.74% and -4.95%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
PROFOUND MEDICL (PROF) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
PROFOUND MEDICL (PROF) delivered earnings and revenue surprises of -43.48% and -1.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Looks Good: Stock Adds 5.4% in Session
by Zacks Equity Research
Profound Medical (PROF) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
PROFOUND MEDICL (PROF) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
PROFOUND MEDICL (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.